Abstract LB207: Continuous subcutaneous lenalidomide delivery improves the therapeutic index and avoids drug-related grade 3/4 hematologic toxicity in patients with relapsed/refractory multiple myeloma

Authors: Nash Gabrail, Keith Lerro, Mohamad A. Hussein, Asher A. Chanan-Khan, Jamie C. Oliver

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-lb207

Source: Full article